article7 June 2024 | By Antje Brambrink (Finnegan), Charles Collins-Chase (Finnegan), Marco Thurner (Finnegan)
Experts at IP firm Finnegan discuss if the pharmaceutical industry is ready for the innovation and technologies that digitalisation and automation will bring, and whether these advances are a threat or ally to intellectual property rights in the sector.